Why the study?
Although the subcutaneous implantable cardioverter defibrillator has seen considerable improvements and clinical adoption, shortcomings remain to be addressed by future generations.
S-ICD is a safe and effective therapy for selected patients, but future generations of the device need to address current shortcomings.
Answers are grounded in this paper and cite their sources.
S-ICD remains a valuable option in selected patients; leaves open need for updated RCTs across broader populations.
INTRODUCTION: The subcutaneous implantable cardioverter defibrillator (S-ICD) is currently in its third generation and has been adopted in guidelines and in mainstream clinical practice. Considerable improvements have been made since the introduction of this device over a decade ago. AREAS COVERED: A literature search was undertaken in Pubmed on articles relating to the S-ICD. EXPERT OPINION: The therapy has been proven to be safe and effective and is a valuable option in selected patients. Nevertheless, there remain many shortcomings of the S-ICD which are discussed in this review, and which hopefully will be addressed by future generations of the device.
No takes yet. Share an insight, caveat, or question.
Friedli et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: